AbiVax and Lexeo Therapeutics are jumping into the lukewarm public waters, each filing an initial public offering late last week as a potentially active fall filing season begins.
The gene therapy startup Lexeo Therapeutics and inflammatory disease biotech Abivax filed paperwork to go public Friday afternoon, as the pre-Thanksgiving IPO window shrinks and a government shutdown looms.
PARIS, FRANCE / ACCESSWIRE / August 10, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The timing, number of securities to be offered in the proposed offering and their price have not yet been determined.
PARIS, FRANCE / ACCESSWIRE / June 8, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on June 5, 2023, which was chaired by Marc de Garidel, CEO of Abivax and interim Chairman of the Board of Directors.
PARIS, FRANCE / ACCESSWIRE / May 15, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 5, 2023, at 10:00 am (CEST), at the offices of Dechert (Paris) LLP, located at 22 rue Bayard in Paris (75008), France.
PARIS, France, May 2nd, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the Journal of Crohn’s and Colitis (JCC) publication of a piece titled “Obefazimod: a first-in-class drug for the treatment of ulcerative colitis”[1], written by global Inflammatory Bowel Disease (IBD) experts.
PARIS, FRANCE / ACCESSWIRE / April 18, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Michael Ferguson as new Chief Commercial Officer, effective immediately, and he will be based at the new Abivax subsidiary on the US East Coast. Therefore, Pierre Courteille will be focusing on business development activities and is appointed Chief Business Officer. Abivax is strengthening its expertise in the commercial and business development field to foster the evolution of the Company towards future commercialization of obefazimod.
Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod Phase 2b Maintenance Trial in Ulcerative Colitis